28-Mar-2024
No headlines found.
LeMaitre to Present at the 23rd Annual Needham Virtual Healthcare Conference
Globe Newswire (Tue, 26-Mar 4:52 PM ET)
LeMaitre to Participate at Upcoming Investor Conferences in March
Globe Newswire (Fri, 1-Mar 4:37 PM ET)
LeMaitre Will Announce Fourth Quarter 2023 Earnings Results February 27, 2024
Globe Newswire (Tue, 13-Feb 10:37 AM ET)
LeMaitre to Present at the 26th Annual Needham Growth Conference
Globe Newswire (Thu, 11-Jan 2:31 PM ET)
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Lemaitre Vascular trades on the NASDAQ stock market under the symbol LMAT.
As of March 28, 2024, LMAT stock price declined to $66.36 with 90,754 million shares trading.
LMAT has a beta of 0.72, meaning it tends to be less sensitive to market movements. LMAT has a correlation of 0.04 to the broad based SPY ETF.
LMAT has a market cap of $1.48 billion. This is considered a Small Cap stock.
Last quarter Lemaitre Vascular reported $49 million in Revenue and $.38 earnings per share. This fell short of revenue expectation by $-137,000 and exceeded earnings estimates by $.02.
In the last 3 years, LMAT stock traded as high as $74.64 and as low as $38.32.
The top ETF exchange traded funds that LMAT belongs to (by Net Assets): IJR, VTI, IWM, VXF, IJT.
LMAT has underperformed the market in the last year with a price return of +31.2% while the SPY ETF gained +33.6%. However, in the short term, LMAT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +15.3% vs +10.1% return in SPY. But in the last 2 weeks, LMAT shares have been beat by the market, returning -0.4% compared to an SPY return of +1.7%.
LMAT support price is $65.83 and resistance is $68.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LMAT stock will trade within this expected range on the day.